David R. Taft

1.4k total citations
58 papers, 925 citations indexed

About

David R. Taft is a scholar working on Oncology, Molecular Biology and Pharmacology. According to data from OpenAlex, David R. Taft has authored 58 papers receiving a total of 925 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 10 papers in Molecular Biology and 10 papers in Pharmacology. Recurrent topics in David R. Taft's work include Drug Transport and Resistance Mechanisms (14 papers), HIV/AIDS drug development and treatment (8 papers) and Pharmacogenetics and Drug Metabolism (6 papers). David R. Taft is often cited by papers focused on Drug Transport and Resistance Mechanisms (14 papers), HIV/AIDS drug development and treatment (8 papers) and Pharmacogenetics and Drug Metabolism (6 papers). David R. Taft collaborates with scholars based in United States, Australia and Sweden. David R. Taft's co-authors include Craig H. Moskowitz, Ann S. LaCasce, Stephen M. Ansell, Nancy L. Bartlett, Tatyana Feldman, Julie M. Vose, Alex F. Herrera, Ranjana H. Advani, Alison J. Moskowitz and Radhakrishnan Ramchandren and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

David R. Taft

55 papers receiving 908 citations

Peers

Countries citing papers authored by David R. Taft

Since Specialization

Citations

This map shows the geographic impact of David R. Taft's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David R. Taft with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David R. Taft more than expected).

Fields of papers citing papers by David R. Taft

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David R. Taft. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David R. Taft. The network helps show where David R. Taft may publish in the future.

Co-authorship network of co-authors of David R. Taft

This figure shows the co-authorship network connecting the top 25 collaborators of David R. Taft. A scholar is included among the top collaborators of David R. Taft based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David R. Taft. David R. Taft is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Impact of Second Opinions on Time to Treatment of Breast Cancer 2025 ·Annals of Surgical Oncology ·(unknown), Andrew K. Conner, (unknown), David R. Taft, Anna Chichura, (unknown), (unknown), (unknown), (unknown), Carol A. Rosenberg, Zahraa Al‐Hilli	0
2	Developing a Formulation Strategy Coupled with PBPK Modeling and Simulation for the Weakly Basic Drug Albendazole 2023 ·Pharmaceutics ·(unknown), Kushal Shah, (unknown), Rutesh H. Dave, David R. Taft	6
3	PBPK Modeling of Azithromycin Systemic Exposure in a Roux-en-Y Gastric Bypass Surgery Patient Population 2023 ·Pharmaceutics ·(unknown), (unknown), (unknown), Pooja Manchandani, David R. Taft	1
4	Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results 2021 ·Blood ·Ranjana H. Advani, Alison J. Moskowitz, Nancy L. Bartlett, Julie M. Vose, Radhakrishnan Ramchandren, Tatyana Feldman, Ann S. LaCasce, Beth Christian, Stephen M. Ansell, Craig H. Moskowitz, Lisa Brown, Chiyu Zhang, David R. Taft, Sahar Ansari, Mariana Sacchi, Linda Ho, Alex F. Herrera	116
5	Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma 2017 ·Blood ·Alex F. Herrera, Alison J. Moskowitz, Nancy L. Bartlett, Julie M. Vose, Radhakrishnan Ramchandren, Tatyana Feldman, Ann S. LaCasce, Stephen M. Ansell, Craig H. Moskowitz, Keenan Fenton, Carol Anne Ogden, David R. Taft, Qu Zhang, Kazunobu Kato, Mary S. Campbell, Ranjana H. Advani	230
6	Evaluating the Potential for Delivery of Irinotecan via the Buccal Route: Physicochemical Characterization and In Vitro Permeation Assessment Across Porcine Buccal Mucosa 2016 ·AAPS PharmSciTech ·Vidhi M. Shah, (unknown), David R. Taft	9
7	Effects of formulation and route of administration on the systemic availability of Ex‐RAD^®, a new radioprotectant, in preclinical species 2011 ·Biopharmaceutics & Drug Disposition ·(unknown), (unknown), David R. Taft, Amanda M. Gillum, Manoj Maniar	6
8	Assessing the impact of employment legislation: The coalition government's labour law program 1996-2007 2010 ·RMIT Research Repository (RMIT University Library) ·Richard Mitchell, David R. Taft, Anthony Forsyth, Peter Gahan, (unknown)	3
9	Renal excretion of clofarabine: Assessment of dose-linearity and role of renal transport systems on drug excretion 2010 ·European Journal of Pharmaceutical Sciences ·(unknown), Peter L. Bonate, David R. Taft	8
10	Renal excretion of emtricitabine I: Effects of organic anion, organic cation, and nucleoside transport inhibitors on emtricitabine excretion 2008 ·Journal of Pharmaceutical Sciences ·(unknown), David R. Taft	17
11	Renal excretion of emtricitabine II. Effect of trimethoprim on emtricitabine excretion: In vitro and in vivo studies 2008 ·Journal of Pharmaceutical Sciences ·(unknown), David R. Taft	7
12	Effects of Trimethoprim on the Clearance of Apricitabine, a Deoxycytidine Analog Reverse Transcriptase Inhibitor, and Lamivudine in the Isolated Perfused Rat Kidney 2006 ·Journal of Pharmacology and Experimental Therapeutics ·(unknown), (unknown), Aruna Dontabhaktuni, David R. Taft	15
13	Application of the Isolated Perfused Rat Kidney Model to Assess Gender Effects on Drug Excretion 2006 ·Drug Development and Industrial Pharmacy ·David R. Taft, Aruna Dontabhaktuni, (unknown), (unknown), (unknown)	2
14	The Isolated Perfused Rat Kidney Model: A Useful Tool for Drug Discovery and Development 2004 ·Current Drug Discovery Technologies ·David R. Taft	27
15	Simulation of the Pharmacokinetic Profile of Methazolamide in Blood: Effect of Erythrocyte Carbonic Anhydrase Binding on Drug Disposition 2002 ·Pharmaceutical Research ·Malaz Abutarif, David R. Taft	1
16	In Vitro Evaluation of the Release of Albuterol Sulfate from Polymer Gels: Effect of Fatty Acids on Drug Transport Across Biological Membranes 2002 ·Drug Development and Industrial Pharmacy ·(unknown), (unknown), David R. Taft, Fotios M. Plakogiannis	15
17	Alternative high-performance liquid chromatographic assay for p-aminohippuric acid (PAH): effect of aging on PAH excretion in the isolated perfused rat kidney 2001 ·Journal of Pharmaceutical and Biomedical Analysis ·(unknown), (unknown), Hassan Almoazen, Stephan Ortiz, Malaz Abutarif, David R. Taft	5
18	In Vitro Characterization of the Erythrocyte Distribution of Methazolamide: A Model of Erythrocyte Transport and Binding Kinetics 1999 ·Journal of Pharmacokinetics and Biopharmaceutics ·(unknown), (unknown), David R. Taft	6
19	Determination of methazolamide concentrations in human biological fluids using high performance liquid chromatography 1998 ·Journal of Pharmaceutical and Biomedical Analysis ·(unknown), David R. Taft	10
20	Evidence for reversible sequestration of morphine in rat liver 1996 ·Biochemical Pharmacology ·Christopher Matheny, David R. Taft, Kim L. R. Brouwer, Gary M. Pollack	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact